

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/Caplus
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	12	APR 26	PROMT: New display field available
NEWS	13	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	14	APR 26	LITALERT now available on STN
NEWS	15	APR 27	NLDB: New search and display fields available
NEWS	16	May 10	PROUSDDR now available on STN
NEWS	17	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS	18	May 12	EXTEND option available in structure searching
NEWS	19	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	20	May 17	FRFULL now available on STN
NEWS	21	May 27	STN User Update to be held June 7 and June 8 at the SLA 2004 Conference
NEWS	22	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in Caplus
NEWS	23	May 27	Caplus super roles and document types searchable in REGISTRY
NEWS	24	May 27	Explore APOLLIT with free connect time in June 2004
NEWS EXPRESS		MARCH 31	CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:44:01 ON 15 JUN 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:44:25 ON 15 JUN 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2004 HIGHEST RN 693217-50-4

DICTIONARY FILE UPDATES: 14 JUN 2004 HIGHEST RN 693217-50-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>


Uploading c:\program files\stnexp\queries\106845735.2

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Cb,Cy,Hy

Patel

<6/15/2004>

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

FULL SEARCH INITIATED 13:47:56 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2959 TO ITERATE

100.0% PROCESSED 2959 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

L2 1 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

157.52

157.73

FILE 'CAPLUS' ENTERED AT 13:48:01 ON 15 JUN 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Jun 2004 VOL 140 ISS 25

FILE LAST UPDATED: 14 Jun 2004 (20040614/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3 1 L2

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:964135 CAPLUS

DN 138:24543

TI Preparation of benzyloxyphenyloxobutyrate and related compounds for the treatment of metabolic disorders

IN Sharma, Shalini; Von Borstel, Reid W.; Hodge, Kirvin L.

PA Wellstat Therapeutics Corporation, USA

SO PCT Int. Appl., 242 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002100341	A2	20021219	WO 2002-US18388	20020612
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003149107	A1	20030807	US 2002-167839	20020612
	US 2004077896	A1	20040422	US 2001-297282PP	20010612
				US 2003-684644	20031014
				US 2001-297282PP	20010612
				US 2002-167839	A320020612
	US 2004092518	A1	20040513	US 2003-684735	20031014
				US 2001-297282PP	20010612
				US 2002-167839	A320020612
	US 2004092516	A1	20040513	US 2003-685183	20031014
				US 2002-167839	A320020612
	US 2004097585	A1	20040520	US 2003-684730	20031014
				US 2001-297282PP	20010612
				US 2002-167839	A320020612
OS	MARPAT 138:24543				
IT	478162-73-1P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of benzyloxyphenyloxobutyrate and related compds. for treatment of metabolic disorders)				
RN	478162-73-1 CAPLUS				
CN	1H-Tetrazole, 5-[[4-[(2,6-difluorophenyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)				



GI



AB Biol. active title compds. [I; n = 1, 2; m, q, p = 0, 1; R5 = alkyl; R9 =

H, halo, alkoxy; A = (halo-, alkyl-, perfluoromethyl-, alkoxy-, perfluoromethoxy-substituted) Ph, (Me-, Et-substituted) cycloalkyl, 5-6 membered heteroarom. ring having 1-2 N, S, O atoms; X = CH₂, Q = OR₁, R₁ = Et; or X = CH₂CR₁₂R₁₃, CH₂CH(NHAc), Q = OR₁, R₁ = H, alkyl; or X = CH₂CH₂, Q = NR₁₀R₁₁; R₁₂, R₁₃ = H, Me; 1 of R₁₀, R₁₁ = H, alkyl, OH, the other = H, alkyl], were prepared Thus, 4-(2-fluorobenzyloxy)acetophenone (preparation given) in THF and DMPU was treated with a solution of Li bis(trimethylsilyl)amide at -60°; after 10 min, tert-Bu bromoacetate was added followed by stirring for an addnl. 10 min and warming to room temperature for 4 h to give tert-Bu 4-[4-(2-fluorobenzyloxy)phenyl]-4-oxobutyrate. The latter was stirred with CF₃CO₂H in CH₂Cl₂ to give 4-[4-(2-fluorobenzyloxy)phenyl]-4-oxobutyric acid. Tested I showed antidiabetic activity in a variety of tests. I are useful in treatment of various metabolic disorders such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis.

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
5.19	162.92

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.69	-0.69

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 13:48:37 ON 15 JUN 2004

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JAN 27 Source of Registration (SR) information in REGISTRY updated
and searchable
NEWS 4 JAN 27 A new search aid, the Company Name Thesaurus, available in
CA/CAPLUS
NEWS 5 FEB 05 German (DE) application and patent publication number format
changes
NEWS 6 MAR 03 MEDLINE and L MEDLINE reloaded
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 8 MAR 03 FRANCEPAT now available on STN
NEWS 9 MAR 29 Pharmaceutical Substances (PS) now available on STN
NEWS 10 MAR 29 WPIFV now available on STN
NEWS 11 MAR 29 New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 12 APR 26 PROMT: New display field available
NEWS 13 APR 26 IFIPAT/IFIUDB/IFICDB: New super search and display field
available
NEWS 14 APR 26 LITAlert now available on STN
NEWS 15 APR 27 NLDB: New search and display fields available
NEWS 16 May 10 PROUSDDR now available on STN
NEWS 17 May 19 PROUSDDR: One FREE connect hour, per account, in both May
and June 2004
NEWS 18 May 12 EXTEND option available in structure searching
NEWS 19 May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS 20 May 17 FRFULL now available on STN
NEWS 21 May 27 STN User Update to be held June 7 and June 8 at the SLA 2004
Conference
NEWS 22 May 27 New UPM (Update Code Maximum) field for more efficient patent
SDIs in CAPLUS
NEWS 23 May 27 CAPLUS super roles and document types searchable in REGISTRY
NEWS 24 May 27 Explore APOLLIT with free connect time in June 2004

NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:38:29 ON 15 JUN 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:38:47 ON 15 JUN 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2004 HIGHEST RN 693217-50-4

DICTIONARY FILE UPDATES: 14 JUN 2004 HIGHEST RN 693217-50-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>


Uploading c:\program files\stnexp\queries\10684735.1

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Cb,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

FULL SEARCH INITIATED 13:39:10 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 20012 TO ITERATE

100.0% PROCESSED 20012 ITERATIONS

32 ANSWERS

SEARCH TIME: 00.00.01

L2 32 SEA SSS FUL L1

=> f ile caplus

L3 0 ILE CAPLUS

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

164.28

164.49

FILE 'CAPLUS' ENTERED AT 13:39:29 ON 15 JUN 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Jun 2004 VOL 140 ISS 25

FILE LAST UPDATED: 14 Jun 2004 (20040614/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L4 43 L2

=> d l4 fbib hitstr abs total

L4 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:41315 CAPLUS

DN 140:105289


TI Cysteinyl leukotriene receptor antagonists for the treatment of respiratory diseases

IN Fujita, Manabu

PA Ono Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 33 pp.

CODEN: PIXXD2



AB The invention is directed to 4H-benzo[1,4]oxazin-3-ones I and their stereoisomers, esters, salts, and prodrugs, useful as peroxisome proliferator activated receptor gamma (PPAR γ) agonists or antagonists [wherein: A = (un)substituted aryl, heterocyclyl, or alkyl; Z1 = H, alkyl, aryl, heterocyclyl, OH or derivs., CO₂H or derivs., NH₂ or derivs., halo, etc.; Z2 = H, halo, alkyl; or Z1Z2 = atoms to form fused aromatic ring; n = 0-3; G = CO₂R1, COCO₂R1, CONR1R2, CF₃, P(O)(OR1)(OR2), SH, tetrazolyl, certain heterocycles, etc.; E = H, alkyl, -CH₂CH₂OC₆H₄(CH₂)_nG; X = H₂, O; R1, R2 = H, alkyl, aryl, heterocyclyl, aralkyl; or R1R2 = atoms to form 5- to 10-membered ring; with addnl. provisos]. Pharmaceutical compns. comprising the compds. and methods of treating conditions such as NIDDM and obesity are also disclosed. Over 130 specific compds. are listed, and 5 of the preferred compds. are claimed. For instance, the silyl-protected intermediate 2-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-2H-1,4-benzoxazin-3(4H)-one (preparation given) underwent a sequence of N-alkylation with Br(CH₂)₆F, desilylation, Mitsunobu reaction with Me (2-hydroxyphenyl)acetate, and alkaline saponification, to give the preferred compound

II. In an agonist intrinsic activity assay for induction of α P2 mRNA production, II gave a 64.9-fold increase over control.

L4 ANSWER 5 OF 43 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:964135 CAPLUS

DN 138:24543

TI Preparation of benzyloxyphenyloxobutyrate and related compounds for the treatment of metabolic disorders

IN Sharma, Shalini; Von Borstel, Reid W.; Hodge, Kirvin L.

PA Wellstat Therapeutics Corporation, USA

SO PCT Int. Appl., 242 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100341	A2	20021219	WO 2002-US18388	20020612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003149107	A1	20030807	US 2001-297282PP 20010612
			US 2002-167839 20020612
US 2004077896	A1	20040422	US 2001-297282PP 20010612
			US 2003-684644 20031014
			US 2001-297282PP 20010612
US 2004092518	A1	20040513	US 2002-167839 A320020612
			US 2003-684735 20031014
			US 2001-297282PP 20010612
US 2004092516	A1	20040513	US 2002-167839 A320020612
			US 2003-685183 20031014
US 2004097585	A1	20040520	US 2002-167839 A320020612
			US 2003-684730 20031014
			US 2001-297282PP 20010612
			US 2002-167839 A320020612

OS MARPAT 138:24543


IT **478162-73-1P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of benzyloxyphenyloxobutyrate and related compds. for treatment of metabolic disorders)

RN 478162-73-1 CAPLUS

CN 1H-Tetrazole, 5-[[4-[(2,6-difluorophenyl)methoxy]phenyl]methyl]- (9CI)
(CA INDEX NAME)




GI




AB Biol. active title compds. [I; n = 1, 2; m, q, p = 0, 1; R5 = alkyl; R9 = H, halo, alkoxy; A = (halo-, alkyl-, perfluoromethyl-, alkoxy-, perfluoromethoxy-substituted) Ph, (Me-, Et-substituted) cycloalkyl, 5-6 membered heteroarom. ring having 1-2 N, S, O atoms; X = CH2, Q = OR1, R1 = Et; or X = CH2CR12R13, CH2CH(NHAc), Q = OR1, R1 = H, alkyl; or X = CH2CH2, Q = NR10R11; R12, R13 = H, Me; 1 of R10, R11 = H, alkyl, OH, the other = H, alkyl], were prepared Thus, 4-(2-fluorobenzyloxy)acetophenone (preparation

given) in THF and DMPU was treated with a solution of Li bis(trimethylsilyl)amide at -60° ; after 10 min, tert-Bu bromoacetate was added followed by stirring for an addnl. 10 min and warming to room temperature for 4 h to give tert-Bu 4-[4-(2-fluorobenzyloxy)phenyl]-4-oxobutyrates. The latter was stirred with $\text{CF}_3\text{CO}_2\text{H}$ in CH_2Cl_2 to give 4-[4-(2-fluorobenzyloxy)phenyl]-4-oxobutyric acid. Tested I showed antidiabetic activity in a variety of tests. I are useful in treatment of various metabolic disorders such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis.


L4 ANSWER 6 OF 43 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:19837 CAPLUS
 DN 136:350405
 TI Novel 5-substituted-1H-tetrazole derivatives as potent glucose and lipid lowering agents
 AU Momose, Yu.; Maekawa, Tsuyoshi; Odaka, Hiroyuki; Ikeda, Hitoshi; Sohda, Takashi
 CS Medicinal Chemistry Research Laboratories II, Takeda Chemical Industries, Ltd., Chuo-ku, Osaka, 540-8645, Japan
 SO Chemical & Pharmaceutical Bulletin (2002), 50(1), 100-111
 CODEN: CPBTAL; ISSN: 0009-2363
 PB Pharmaceutical Society of Japan
 DT Journal
 LA English
 IT **166253-98-1P 421558-54-5P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of oxazolylalkoxyphenylalkyltetrazoles as antihyperglycemic and antihyperlipidemic agents)
 RN 166253-98-1 CAPLUS
 CN 1H-Tetrazole, 5-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-(9CI) (CA INDEX NAME)



RN 421558-54-5 CAPLUS
 CN 1H-Tetrazole, 5-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-(9CI) (CA INDEX NAME)



GI



AB A series of 5-(4-alkoxyphenylalkyl)-1H-tetrazole derivs. containing an oxazole-based group at the alkoxy moiety was prepared; the antidiabetic and antihyperlipidemic effects of members of the series were evaluated in two genetically obese and diabetic animal models. The tetrazole compds. were prepared using the cycloaddns. of azides with the corresponding nitriles. Many of the 5-(4-alkoxyphenylalkyl)-1H-tetrazoles showed potent glucose and lipid lowering activities in KKAY mice. Methylphenyloxazolylmethoxypropyltetrazole I had potent glucose lowering activity (ED₂₅ = 0.0839 mg·kg⁻¹·d⁻¹), being 72 times more active than pioglitazone hydrochloride (ED₂₅ = 6.0 mg·kg⁻¹·d⁻¹); in addition, I also exhibited strong antihyperlipidemic activity (ED₂₅ = 0.0277 mg·kg⁻¹·d⁻¹) in Wistar fatty rats. The antidiabetic activity of I is likely related to its potent agonistic activity for peroxisome proliferator-activated receptor γ (PPAR γ) (EC₅₀ = 6.75 nM).

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 43 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:2786 CAPLUS

DN 136:37609

TI Tetrazole derivatives as hypoglycemic and hypolipidemic agents

IN Soda, Takasi; Ikeda, Hitosi; Momose, Yu

PA Takeda Chemical Industries, Ltd., Japan

SO Russ., No pp. given

CODEN: RUXXE7

DT Patent

LA Russian

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	RU 2144533	C1	20000120	RU 1994-43788	19941209
				RU 1994-43788	19941209

OS MARPAT 136:37609

IT **166253-98-1P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(tetrazole derivs. as hypoglycemic and hypolipidemic agents)

RN 166253-98-1 CAPLUS

CN 1H-Tetrazole, 5-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-(9CI) (CA INDEX NAME)